On the Ground in China Trials - Applied Clinical Trials

ADVERTISEMENT

See our 2013 Buyers Guide Digital Edition.
On the Ground in China Trials

Source: Applied Clinical Trials

Kent Thoelke, Executive Vice President, Scientific & Medical Affairs for PRA, spoke at the Partnerships conference regarding trial conduct differences in China, featuring what seemed to be very practical, hands-on advice.

For example, in China on the patient or participant side, family engagement throughout the clinical trial is also key. In China, patients keep and carry their health records. While the country is investing in EMRs, right now it’s still a very basic process.

Also, in China, traditional medicine is still used primarily by the Chinese for a number of reasons and conditions. These concomitant medicines can play a role in drug metabolism, so it is important to verify with the patients what they are taking.

In addition, Thoelke noted there is a difference of treatment between socio-economic classes. Specifically, the standard of care vs. the “usual care.”

On the business side, most global CROs have a relationship with a local CRO, which Thoelke stresses is important to navigating the cultural and regulatory norms. And he stressed that relationships are key in China. The investigator community is very networked, which he acknowledged can make negotiations and contracts difficult because the investigators know and share that information.

He also said, because of these relationships, the way to do site feasibility is to go to the site. “You can’t do feasibility like anywhere else in the world,” Thoelke noted. “You have to go there.”

Following Thoelke’s presentation was R. Stephen Porter, PharmD, FCP, with VDDI Pharmaceuticals. Porter spoke frankly to other issues in China, which can be related to fraud or corruption. He noted that there is a clamp down on corruption in China, and he specifically referred to the execution of the former SFDA’s chief for corruption in 2007. Another difference at the SFDA, besides having 200 reviewers vs. 2,034 at the US FDA, is that a reviewer is held responsible for an approval for the rest of their life. So the wiggle room for scientific developments or safety issues in larger populations is not the same as here.

However, outside of that, other issues that come into play include that 51% of hospital revenues in China come from pharmaceutical prescriptions. This practice has led to what Porter calls unintended consequences, specifically in the over-dispensation of antibiotics leading to a very high rate of MRSA and c. Difficile.

Another unintended consequence may be the underreporting of adverse events. Culturally, Chinese people won’t complain about a doctor’s care, and that they may be embarrassed to report an adverse event. Also, culturally, Porter said that there is a huge patient blogsphere in China, and other communications include texting and social media platforms such as WeChat. 

And to put in perspective what China looks like today, there are 530 approved clinical trial centers in the country compared to 55,000 in the United States. China is rapidly approving these centers, but that is the status now.

ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

8th Annual Forum on Transparency and Aggregate Spend 2014
Washington, DC
August 18-20, 2014

eSource Data in Clinical Investigations
Philadelphia, PA
August 20-21, 2014

Pharmacovigilance 2014
Philadelphia, PA
September 10-11, 2014

Collaborative Research Summit
Philadelphia, PA
October 15-16, 2014

See All Conferences >>

Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
87%
Borrow lightly from EMA's pathway program?
6%
Create entirely its own pathway program?
8%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here